BerandaDCTH • NASDAQ
add
Delcath Systems Inc
Tutup sebelumnya
$8,70
Rentang hari
$8,39 - $8,82
Rentang tahun
$2,25 - $9,18
Kapitalisasi pasar
241,74Â jt USD
Volume Rata-Rata
245,26Â rb
Rasio P/E
-
Hasil dividen
-
Bursa utama
NASDAQ
Dalam berita
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
(USD) | Mar 2024info | Perubahan Y/Y |
---|---|---|
Pendapatan | 3,14Â jt | 425,80% |
Biaya operasional | 12,51Â jt | 43,16% |
Laba bersih | -11,11Â jt | -23,46% |
Margin laba bersih | -353,97 | 76,52% |
Penghasilan per saham | -0,45 | 41,56% |
EBITDA | -10,25Â jt | -23,56% |
Tarif pajak efektif | — | — |
Neraca
Total aset
Total liabilitas
(USD) | Mar 2024info | Perubahan Y/Y |
---|---|---|
Investasi tunai jangka pdk | 27,12Â jt | 11,96% |
Total aset | 36,10Â jt | 17,97% |
Total liabilitas | 21,48Â jt | 5,46% |
Total ekuitas | 14,62 jt | — |
Saham yang beredar | 27,79 jt | — |
Harga terhadap reservasi | 15,26 | — |
Tingkat pengembalian aset | -68,78% | — |
Pengembalian modal | -94,05% | — |
Arus Kas
Perubahan bersih tunai
(USD) | Mar 2024info | Perubahan Y/Y |
---|---|---|
Laba bersih | -11,11Â jt | -23,46% |
Kas dari operasi | -9,58Â jt | -124,77% |
Tunai dari investasi | 4,66 jt | — |
Tunai dari pembiayaan | 4,02Â jt | -75,91% |
Perubahan bersih tunai | -886,00Â rb | -107,12% |
Arus kas bebas | -5,53Â jt | -298,75% |
Tentang
Delcath Systems, Inc. is a publicly traded specialty pharmaceutical and medical device company, that develops percutaneous perfusion technologies for the targeted administration of high-dose chemotherapeutic agents to specific organs or regions of the body. Based in Queensbury, New York, the company has an intellectual property portfolio consisting of 28 patents worldwide. Delcath's Percutaneous Hepatic Perfusion is currently undergoing Phase II and Phase III trials against tumors in the liver. Delcath has a Cooperative Research and Development Agreement with the National Cancer Institute and has received Fast Track and a Special Protocol Assessment from the Food and Drug Administration for its use of melphalan in treating unresectable liver tumors. PHP, also known as the Delcath System, is tested for the treatment of metastatic melanoma in the liver and for primary liver cancer and metastatic hepatic malignancies from neuroendocrine cancers and adenocarcinomas, as well as patients with melanoma who previously received isolated perfusion. Chemotherapy is usually delivered intravenously, although a number of agents can be administered orally. Wikipedia
Didirikan
1988
Kantor pusat
Situs
Karyawan
76